New transparency policies have created a tension between the regulatory obligation to post clinical trials early and the desire to obtain patent protection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Price, W.N., II & Minssen, T. Nat. Biotechnol. 33, 685–686 (2015).
Kallenbach, L. & Vallazza, M. epi® Information 4/17, 36–43 (2017).
EPO's Technical Board of Appeal decision T 433/05 (2007).
EPO's Technical Board of Appeal decisions T 1364/08 (2010), T 1255/11 (2017), and T 950/13 (2017).
EPO's Technical Board of Appeal decision T 488/16 (2017).
EPO's Technical Board of Appeal decision T 1045/13 (2017).
EPO's Technical Board of Appeal decision T 609/02 (2004).
EPO's Technical Board of Appeal decisions T 1616/09 (2014) and T 45/12 (2015).
EPO's Technical Board of Appeal decision T 2506/12 (2016).
EPO's Technical Board of Appeal decision T 158/96 (1998).
EPO's Technical Board of Appeal decision T 715/03 (2006).
EPO's Technical Board of Appeal decision T 385/07 (2007).
EPO's Technical Board of Appeal decision T 239/16 (2017).
EPO's Technical Board of Appeal decision T 725/11 (2017).
ImpaxLabs. Inc. v. Aventis Pharm. Inc., 468 F.3d 1366, 1383 (Fed. Cir. 2006).
Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1352 (Fed. Cir. 2010) (citing Falko-Gunter Falkner v. Inglis, 448 F.3d 1357, 1366–67 (Fed. Cir. 2006)).
The Standing Committee on Pharma and Biotechnology. AIPPI position paper re recommendations on the use of post-filing data in support of inventive step (2017).
Acknowledgements
The discussion herein represents the personal views of the authors and not the views of the authors' company.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kallenbach, L., Vallazza, M. Are the new clinical trial transparency rules incompatible with the patentability requirements in Europe?. Nat Biotechnol 36, 928–930 (2018). https://doi.org/10.1038/nbt.4265
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4265
This article is cited by
-
Exploring the technology–healthcare expenditure nexus: a panel error correction approach
Empirical Economics (2022)